Available Until 9/15/2024

Breast Cancer: An Overview and Current Treatment Strategies

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.


A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities

Activity Description

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.

Breast cancer is the most common cancer diagnosis and the 2nd leading cause of cancer death among women in the United States. As a molecularly heterogeneous disease, full knowledge of clinical and biological features is crucial to providing a personalized treatment approach for patients with early stage and metastatic disease. This educational activity will provide an overview of the epidemiology, risk factors, pathology, and staging of breast cancer. Standard treatment regimens for non-metastatic and metastatic disease will be reviewed with a focus on oral chemotherapy and targeted therapies. Strategies for early identification and management of treatment-related adverse events will be reviewed in detail.

Learning Objectives

The target audience for this activity includes pharmacists and nurses. Upon completion of this activity, participants will be able to:

  • Describe the epidemiology, risk factors, and pathology of breast cancer.
  • Discuss the screening, diagnosis, and staging of breast cancer.
  • Review standard treatment regimens for adjuvant and metastatic breast cancer by subtype.
  • Discuss common side effects and monitoring parameters for oral therapies.
  • Outline proactive side effect management and counseling to maximize compliance with oral therapies.


Kristina F. Byers, PharmD, BCOP
Clinical Pharmacy Specialist, Breast Oncology
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia

CME/CE Accreditation

Release Date: September 15, 2021
Expiration Date: September 15, 2024

ACPE Credit Designation (Pharmacist CE)

This CE activity is jointly provided by ProCE, LLC and the National Association of Specialty Pharmacy (NASP). ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-247-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 2.5 contact hour (0.25 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.5 contact hours.


It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty and planners reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Kristina Byers has received consulting fees from Seattle Genetics and Wellstat Therapeutics.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Laly Havern does not have any relevant conflicts of interest to report.
Robin Wanous-Williamson (nurse planner) has no relevant conflicts of interest to report.

Potential conflicts of interest were resolved with a peer review process provided by Laly Havern, PharmD, MS, BCACP.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


This continuing education activity is supported by an educational grant from AllianceRx Walgreens Prime.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.